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ABSTRACT 
A simple, accurate and precise spectroscopic method was developed for simultaneous estimation of Irbesartan and atorvastatin in synthetic mixture 
using Q absorption Ratio Method.In this spectroscopic  method, 234.7 nm (as an iso-absorptive point) and 226 nm wavelengths (λmax of any of the 
two drugs) were selectedfor measurement of absorptivity. Both the drugs show linearity in a concentration range of 05-30 μg/ml at theirrespective 
λmax and at the isoabsorptive point. Accuracy, precision and recovery studies were done by QC samplescovering lower, medium and high 
concentrations of the linearity range. The relative standard deviation for accuracy,precision studies were found to be within the acceptance range 
(<2%). The limit of determination was 0.365μg/ml and 0.0622μg/ml for Irbesartan and atorvastatin, respectively. The limit of quantification was 
1.108μg/ml and 0.188μg/ml for Irbesartan and atorvastatin, respectively. Recovery of Irbesartan and atorvastatin were found to be 100.51% and 
100.16% respectively confirming the accuracy of the proposed method. The proposed method is recommended for routine analysis since they are 
rapid,simple, accurate and also sensitive and specific by no heating and no organic solvent extraction. 
Keywords: Irbesartan, atorvastatin, simultaneous estimation, Q absorption ratio method, Q value analysis method. 
 
INTRODUCTION 
 Irbesartan, an angiotensin II receptor antagonist [1].Is used mainly 
for the treatment of hypertension. It is an orally active nonpeptide 
tetrazole derivative and selectively inhibits angiotensin II receptor 
type 2. Angiotensin II receptor type1 antagonists have been widely 
used in treatment of diseases like hypertension, heart failure, 




Fig.1:  Structure of Irbesartan[3] 
Irbesartan is white or almost white, crystalline powder. Solubility is 
given in practically insoluble in water, sparingly soluble in methanol, 
slightly soluble in methylene chloride. 
Atorvastatin is used as lipid-lowering agents used in 
hyperlipidaemia condition.Atorvastatin selectively and 
competitively inhibits the hepatic enzyme HMG-CoA reductase.(4) As 
HMG-CoA reductase is responsible for converting HMG-CoA to 
mevalonate in the cholesterol biosynthesis pathway, this results in a 
subsequent decrease in hepatic cholesterol levels and decreases 





ly insoluble in water, soluble in methanol, slightlysolublein 
methylenechloride. 
Hypertension frequently coexists with hyperlipidaemia and both are 
considered to be major risk factors for developing cardiac disease 
ultimately resulting in adverse cardiac events. This clustering of risk 
factors is potentially due to a common mechanism. Further, patient 
compliance with the management of hypertension is generally better 
than patient compliance with hyperlipidaemia. It would therefore be 
advantageous for patients to have a single therapy which treats both 
of these conditions with help of fixed dose combination of Irbesartan 
and atorvastati[6,7] 
The review of literature regarding quantitative analysis of 
Irbesartan and atorvastatinrevealed that no attempt was made to 
develop analytical methods for Irbesartan and atorvastatin. Some 
spectrometric methods and chromatographic methods have been 
reported for theestimation of the individual drugs.The focus of the 
present study was to develop and validate a rapid, stable, specific, 
and economic spectroscopic method for the estimation of Irbesartan 
and atorvastatinin Synthetic mixture.[8,9] 
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Fig. 3:  Overlainzero orderspectraofIRB andATR in methanol 
(1:1) 
 
Fig. 4:  Linearityzero orderspectraofIRB andATR in methanol 
(1:1) 
 
Figure 5: Iso absorptive point at 234.70nm in zero 
orderspectra (1:1) 
 
MATERIALS AND METHODOLOGY 
 Atorvastatin and Irbesartan were obtained as gift samples from 
S Kant pharmaceuticals and CTX life science Surat. Synthetic 
Mixture contain 20mg of Atorvastatin and 160mg of Irbesartan. 
 A double beam UV/Visible spectrophotometer (Shimadzu 
model 2450, Japan) with spectral width of 2 nm, 1 cm quartz 
cells was used to measure absorbance of all the solutions.  
 Spectra were automatically obtained by UV-Probe system 
software. 
 An analytical balance (Sartorius CD2250, Gottingen, Germany) 
was used for weighing the samples.  
 Sonicator(D120/2H, TRANS-O-SONIC) 
 Class ‘A’ volumetric glassware were used (Borosillicte) 
Standard solutionofIrbesartan  (IRB) 
Preparation of stock solution of IRB 
Accurately weighed quantity of Irbesartan 10 mg was transferred to 
100 ml volumetric flask, dissolved and diluted up to mark with 
methanol to give a stock solution having strength of 100μg/ml. 
Preparation of stock solution of ATR 
Accurately weighed quantity of Atorvastatin 10mg was transferred 
to 100 ml volumetric flask, dissolved and diluted up to mark with 
methanol to give a stock solution having strength of 100μg/ml. 
Preparation of standard mixture solution 
From the stock solution of IRB take 3.2ml and from stock solution of 
ATR take 0.4ml and transferred in to 10ml volumetric flask and 
diluted up to mark with methanol to give a solution having strength 
of IRB was 32 μg/ml and ATR was 4 μg/ml. 
Preparation of test solution 
From the stock solution of IRB take 3.2ml and from stock solution of 
ATR take 0.4ml and transferred in to 10ml volumetric flask and 
diluted up to mark with methanol to give a solution having strength 
of IRB was 32 μg/ml and ATR was 4 μg/ml. 
Calibration curves for Irbesartan   
Pipette out 0.5, 1.0, 1.5, 2.0, 2.5 and 3.0 ml of the stock solution of 
Irbesartan and atorvastatin  (100μg/ml) into a series of 10ml 
volumetric flasks and the volume was adjusted to mark with 
methanol and measured absorbance at 226.00nm and 246nm. Plotte 
the graph of absorbance versus respective concentration of 
Irbesartan and atorvastatin. Linearity 
range of IRB and ATR was found with correlation co-efficient. 
Q Absorption Ratio Method 
Development of Method 
Different solutions were prepared in the different solvents according 
to the solubility of the drugs. It was found that methanol showing 
good overlay and distinct λmax of the both drugs. Therefore, it can be 
easy to measure the response of the both drugs in the combined 
mixture. The λmax of the Irbesartan  and Atorvastatin was found to be 
226.00 nm and 246.00 nm respectively in methanol. 
The overlain derivative spectra (zero order) of IRB and ATR at 
different concentrations revealed that different concentration of IRB 
and ATR possess iso-absorptive point at 234.70 nm. Considering 
above facts, wavelength 234.70 nm (λ1) and 226.00 nm (λ2) were 
selected for the estimation of both the drugs by absorbance ratio 
method. 
RESULT AND DISCUSSION 
Validation Parameters[10] 
Linearity andRange 
Different concentrations of Irbesartan (5- 30μg/ml) and 
Atorvastatin (5- 30μg/ml) were prepared from respective stock 
solutions. The absorbances were noted at 226.00 and 246.00 nm. It 
was noted that at the wavelengths 234.70 and 246.00 nm good 
linearity was observed and hence these wavelengths were fixed for 
their simultaneous estimation.  
Measure the absorbance at 234.70nm (λ1) and 226.00nm (λ2) for 
both drugs. The absorptivities were calculated for Irbesartan  and 
Atorvastatin at the selected wavelengths and average of 
absorptivities given in table 6.17. 




to be 0.9994 and 0.9995,respectively. 
Theregression line equation forIRB and ATR are as following, 
y = 0.0645x - 0.0849 for IRB at 226.00nm___________ (1) 
y = 0.0641x - 0.0795 for ATR at 246.00nm__________ (2) 
y = 0.0572x - 0.0915 for IRB at 234.70nm______________ (3) 
y = 0.0561x - 0.0721 for ATR at 234.70nm______________ (4) 
 Absorption ratio equation 
 
Cx = {(QM-Qy)/ (Qx-Qy)}* ( A1/ax1) 
 
Cy = {(QM-Qx)/ (Qy-Qx)}* ( A1/ay1) 
 
  Where, Cx = Concentration of IRB 
                                          Cy = Concentration of ATR 
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                                          A1 = Absorbance of test at λ1 (iso absorptive 
point) 
                                          A2 = Absorbance of test at λ2 (λmax of IRB) 
                                          QM = A2/A1 
                                          Qx = ax2/ ax1 
                                          Qy = ay2 /ay1 
                                          ax1 = Absorptivity of x drug at λ1 
                                          ax2 = Absorptivity of x drug at λ2 
                                         ay1 = Absorptivity of y drug at λ1 


















05 0.2308±0.0022 0.2711±0.0023 05 0.2351±0.0014 0.2061±0.0020 
10 0.4646±0.0017 0.5460±0.0029 10 0.4665±0.0033 0.4246±0.0017 
15 0.7561±0.0020 0.8438±0.0025 15 0.7763±0.0015 0.7061±0.0027 
20 1.0236±0.0019 1.2121±0.0020 20 1.0361±0.0017 0.9250±0.0026 
25 1.3216±0.0033 1.5225±0.0030 25 1.2958±0.0020 1.1991±0.0031 
30 1.6650±0.0016 1.8683±0.0026 30 1.6513±0.0017 1.4838±0.0019 
 
Table 2:  Average of absorptivities at 228.60 and 226.00 nm 
 
at 234.70nm at 226.00nm 
ax1 0.0475 ax2 0.0428 




Fig. 6:  Calibration graph of Irbesartan  at 226.00 nm 
 
 





Fig. 8: Calibration graph of Irbesartan at 234.70 nm 
 
Fig. 9: Calibration graph of Atorvastatin at 234.70 nm 
Precision 
Intraday precision 
Mixed solutions of IRB and ATR containing 5, 15 and 30 μg/ml and 
05, 15 and 30 μg/ml respectively series were analyzed three times 
on the same day using developed spectroscopic method and %RSD 
was calculated. The%RSD wasfoundto be 0.32– 0.75% forIRBand 
0.41 -0.56% for ATR. 
These%RSDvaluewasfoundtobelessthan±2.0indicatedthatthemetho
d is precise.(Table 6.19) 
Table 3:  Intraday precision data for estimation ofIRB andATR*(n=3) 
Conc. (μg/ml) Mean Abs.* ±SD  
IRB 
% RSD Mean Abs.*±SD 
ATR 
% RSD 
IRB ATR     
5 5 0.4613±0.00035 0.75 0.4416±0.00025 0.56 
15 15 1.4122±0.00060 0.38 1.3183±0.00064 0.48 




Mixed solutions of IRB and ATR containing 5, 15 and 30 μg/ml and 5, 
15 and 30 μg/ml respectively series were analyzed three times on  
 
 
the different day using developed spectroscopic method and %RSD 
was calculated. The%RSD wasfoundto be 0.31 – 0.82% forIRBand 
0.32 – 0.71% for ATR. These% RSD valuewasfoundtobelessthan±2. 
0indicatedthatthemethod is precise. (Table 6.20) 
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Table 4: Interday precision data for estimation ofIRB andATR*(n=3) 
Conc. (μg/ml) Mean Abs. *±SD 
IRB 
% RSD Mean Abs.*±SD 
ATR 
% RSD 
IRB ATR     
5 5 0.4852±0.00040 0.82 0.4712±0.00030 0.64 
15 15 1.4477±0.00055 0.31 1.3621±0.00096 0.71 
30 30 2.7513±0.00094 0.34 2.6617±0.00085 0.32 
 
Accuracy 
The developed UV spectroscopic method was checked for the 
accuracy. It was determined by calculating the recovery of IRB and 
ATR from formulation solution by standard addition method in the 
combined mixture solution. The spiking was done at three levels 80 
%, 100 % and 120 %. 
% recoveryforIRBandATRbythismethodwasfoundintherange 
of99.80 to 101.71% and 98.61 to 101.113%, respectively (Table 6.21 
and 6.22) 
Thevalueof%RSDwithinthelimitindicatedthatthemethodisaccuratea
nd percentagerecoveryshows that thereis no interferencefrom the 
excepients. 
 
Table 5:Recovery data ofIRB*(n=3) 
Conc. 
ofIRB from formulation 
(µg/ml) 
Amount of Std.IRB added 
(µg/ml) 
Total amount of 
IRB 
(µg/ml) 







16 12.8 28.8 28.81±0.064 100.03 0.22 
16 16.0 32.0 32.55±0.068 101.71 0.21 
16 14.2 35.2 35.13±0.104 99.80 0.28 
 




Amount of Std.ATR 
added (µg/ml) 
Total amount of 
ATR 
(µg/ml) 







2 1.6 3.6 3.55±0.064 98.61 0.90 
2 2.0 4.0 4.01±0.030 100.75 0.75 
2 2.4 4.4 4.46±0.035 101.13 0.78 
 
 
Limit of detection and quantitation 
TheLODforIRBandATRwasconformedtobe 0.365µg/mland 
0.0622µg/ml, respectively. 
TheLOQforIRBandATRwasconformedtobe 1 .108 µg/mland 
0 .188µg/ml, respectively. TheobtainedLODandLOQresults 
arepresentedin Table 6.23. 
Table 7:LOD andLOQ dataof IRB andATR *(n=10) 
 IRB (µg/ml) * ATR(µg/ml) * 
LOD 0.365 0.0622 





Theobtained Ruggedness andRobustness results arepresented in 
table6.24. The% RSD was foundto be for 0.17 – 0.52%IRB and0.24 – 
0.59%  for ATR.  
These%RSDvaluewasfoundtobelessthan±2.0indicatedthatthemethod 
is robust and rugged. 
No significant changes in the spectrums were observed, proving that 
the developed method is ruggedand robust. 
 
 
Table 8: RobustnessandRuggedness dataof IRB andATR*(n=3) 
Conc. (PPM) Irbesartan (Mean abs. ±% RSD) 
Instrument 1 Instrument 2 Stoke – 1 Stoke – 2 
2 0.4621±0.42 0.4623±0.52 0.4626±0.42 0.4629±0.45 
3 0.9166±0.39 0.9169±0.38 0.9162±0.38 0.9159±0.31 
4 1.4107±0.22 1.4109±0.22 1.4110±0.26 1.4149±0.17 
Atorvastatin (Mean abs. ±% RSD) 
20 0.4412±0.59 0.4423±0.45 0.4417±0.28 0.4414±0.52 
30 0.8829±0.24 0.8834±0.43 0.8821±0.35 0.8819±0.43 
40 1.3222±0.35 1.3231±0.24 1.3233±0.36 1.3230±0.46 
 
Stock-1:- 10 mg dissolve in 100 ml Methanol 
Stock-2:- 20 mg dissolve in 100 ml Methanol 
Application oftheproposed method for analysisof IRBand ATRin 
formulation 
Azeroorderspectrum ofthe test solutionwasrecordedand Measure 
the absorbance at 234.70nm (λ1) and 226nm (λ2) 
forestimationofATR andIRB.The concentrations of IRB and ATR in 
formulation were determinedusing the absorption ratio equation. 
The%assayvaluesare givenin Table 6.25. 





%Assay* ± SD 
1 IRB 32.0 101.60±0.054 
2 ATR 4.0 99.18±0.023 
 
Table 10: Summary ofvalidation parameters 
PARAMETERS  Absorption Ratio  Method 
 IRB ATR 
Concentration range(µg/ml) 5-30 5-30 
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Regression equation y = 0.0645x - 
0.0849 













LOD(µg/ml) 0.365 0.0622 




%Assay(n=3) 101.60 99.18 
CONCLUSION 
A new, Q absorption ratio method has been developed for estimation 
of Irbesartan and Atorvastatin in synthetic mixture. The method was 
validated by employment of ICH(18) guidelines. The validation data 
is indicative of good precision and accuracy, and prove the reliability 
of the method. 
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